This report was our free report of the day on a previous date — it has since expired.
Today's free report is available: MU 10-K — Micron revenue triples to $133.2B on AI demand; operating income hits $99.3B
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Nasdaq Delisting Notice (new) — The company received a Nasdaq deficiency notice for failing the minimum stockholders' equity requirement, and separately for board and committee composition deficiencies, putting its listing at risk.
Tempest Therapeutics' net loss narrowed to $5.2M in the second quarter from $7.9M a year earlier, but its cash position fell sharply to $779,000 as of June 30, 2026, and the company faces Nasdaq delisting risk.
Filed August 13, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~1 min read
Key Changes
-
high
The company received Nasdaq deficiency notices in May 2026 for failing the minimum stockholders' equity requirement and for board and committee composition deficiencies, putting its listing at risk.
-
high
Cash and cash equivalents fell 89.9% to $779,000 as of June 30, 2026, from $7.7M at December 31, 2025, and the company's stockholders' equity turned negative at -$1.1M, including the acquired in-process research and development charge.
-
medium
Research and development expense excluding acquired in-process costs decreased 53.0% to $1.8M in the quarter, while general and administrative expense declined 16.2% to $3.4M.
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Partner
Trade TPST commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 13, 2026 · How we verify